000 02376cam a2200349 a 4500
003 EG-GiCUC
005 20250223031457.0
008 160419s2015 ua h f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.04.Ph.D.2015.Ah.P
100 0 _aAhmed Mokhtar Sllam
245 1 4 _aThe predictive value of serum vascular endothelial growth factor in response to transarterial chemoembolisation in hepatocellular carcinoma /
_cAhmed Mokhtar Sllam ; Supervised Nasr Mohammed Allahloubi , Abdelrahman Nabawy Zekri , Hanan Ramadan Nassar
246 1 5 _aالقيمة التنبؤية لعامل نمو بطانة الأوعية فى المصل تأثرا بالحقن الكيميائى السدى للشريان الكبدى عن طريق القسطرة فى سرطان الكبد
260 _aCairo :
_bAhmed Mokhtar Sllam ,
_c2015
300 _a216 P. :
_bfacsimiles ;
_c30cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology - Medical
520 _aIn the current study 63 newly diagnosed HCC patients were recruited, between June 2012 and June 2013. 35 of them underwent TACE as a primary treatment modality (group A), while 28 of them (group B) were not candidates for immediate TACE. VEGF serum levels were measured using ELISA on days 0, 4, and 30 of TACE in group A, and days 0, 4, and 30 of recruitment in group which was considered a control group to assess potential variation of VEGF over time in the non-intervention group. VEGF serum level was found to correlate with advanced HCC tumor stage, with the higher levels observed in patients with more advanced disease. VEGF serum levels (baseline, day 4,and day 30) were also found to be predictive for PFS, OS, and response in HCC patients treated by TACE. Higher levels were associated with worse outcome
530 _aIssued also as CD
653 4 _aHepatocellular carcinoma
653 4 _aTransarterial chemoembolisation
653 4 _aVascular endothelial growth factor
700 0 _aAbdelrahman Nabawy Zekri ,
_eSupervisor
700 0 _aHanan Ramadan Nassar ,
_eSupervisor
700 0 _aNasr Mohammed Allahloubi ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c56086
_d56086